Information Provided By: 
Fly News Breaks for June 4, 2019
ADMA
Jun 4, 2019 | 08:40 EDT
Jefferies analyst Anthony Petrone started ADMA Biologics with a Buy rating and $8 price target. The analyst sees the launches of BIVIGAM and ASCENIV bringing the company to breakeven by 2021 and $240M in sales within five years. He views ADMA as an attractive way to play the $12B intravenous immunogloblin market.
News For ADMA From the Last 2 Days
ADMA
Apr 25, 2024 | 10:38 EDT
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Biohaven Pharmaceutical... To see the rest of the story go to thefly.com. See Story Here
